QualityStocksNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) Highlighted in Comprehensive Research Report
Willow Biosciences (CSE: WLLW), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, was recently covered in a research report by Eight Capital. Per the report, Eight Capital issued a ‘Buy’ rating and a target price of $4.50 for WLLW, determined in part by Willow’s chosen method of cannabinoid production, biosynthesis, which holds the potential to disrupt the industry. The report also detailed upcoming catalysts for the company, including the potential formation of partnerships and agreements; quantitative milestones demonstrating increased throughput of the company’s proprietary yeast strains; planned uplisting to the Toronto Stock…